Local Ablative Therapy (LAT)

PROCEDURE3 trials

Sponsors

National Cancer Institute (NCI), Gitte Fredberg Persson MD PhD, Groupe Francais De Pneumo-Cancerologie

Conditions

Ablation TechniquesLung AdenocarcinomaLung NeoplasmsMetastasesNSCLCOligometastatic DiseaseRadiotherapyStereotactic Radiation

Phase 2

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

CompletedNCT02759835

National Cancer Institute (NCI)Lung Adenocarcinoma, Lung Neoplasms

Start: 2016-04-13End: 2022-09-20Updated: 2024-06-07

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

RecruitingNCT06620835

Groupe Francais De Pneumo-CancerologieNSCLC

Start: 2025-06-19End: 2030-10-01Target: 45Updated: 2026-04-29

Unknown Phase

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease

RecruitingNCT06356779

Gitte Fredberg Persson MD PhDAblation Techniques, Metastases, Oligometastatic Disease +3

Start: 2024-04-15End: 2035-12-31Target: 1200Updated: 2024-04-16

Related Papers

Longitudinal Circulating Tumor DNA Analysis in Blood and Saliva for Prediction of Response to Osimertinib and Disease Progression in EGFR-Mutant Lung Adenocarcinoma

Cancers2021-07-0324 citations

Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma

The FASEB Journal2020-04-01

Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC.

Journal of Clinical Oncology2019-05-20

Abstract CT106: Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib

Cancer Research2018-07-014 citations

Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.

Journal of Clinical Oncology2018-05-207 citations

Local ablative therapy (LAT) for oligoprogressive, <i>EGFR</i>-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.

Journal of Clinical Oncology2017-05-204 citations